16 terminated. 16 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 16 | Terminated 16 |
| Phase 1 | 1 | Terminated 1 |
Follow Cholestasis: new trials by email Literature Review of Cholestasis trials Research Report on Cholestasis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Placebo-controlled Study of Volixibat in Subjects With Elevated Serum Bile Acids Associated With Intrahepatic Cholestasis of Pregnancy (OHANA) Volixibat, Placebo - Intrahepatic Cholestasis of Pregnancy | Phase 2 | Terminated | Mirum Pharmaceuticals, Inc. | 4 | 2021-01-04 | 2024-08-06 |
| Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Participants With PBC Obeticholic acid, Bezafibrate 200 MG, OCA Placebo - Primary Biliary Cholangitis | Phase 2 | Terminated | Intercept Pharmaceuticals | 75 | 2019-10-02 | 2026-07-16 |
| Study to Evaluate the Safety and Efficacy of Oral CR845 (Difelikefalin) in Patients With Primary Biliary Cholangitis (PBC) and Moderate-to-Severe Pruritus CR845 1.0 mg, Placebo - Cholestatic Pruritus | Phase 2 | Terminated | Cara Therapeutics, Inc. | 14 | 2019-06-25 | 2023-07-03 |
| A Study of Baricitinib (LY3009104) in Participants With Primary Biliary Cholangitis Who do Not Respond or Cannot Take UDCA Baricitinib, Placebo - Primary Biliary Cholangitis | Phase 2 | Terminated | Eli Lilly and Company | 2 | 2019-03-28 | 2020-10-14 |
| Non-comparative Study of BCD-085 in Combination With UDCA in Patients With Primary Biliary Cholangitis BCD-085 - Liver Cirrhosis, Biliary | Phase 2 | Terminated | Biocad | 9 | 2018-04-27 | 2019-10-11 |
| Safety, Tolerability, and Efficacy of Etrasimod (APD334) in Participants With Primary Biliary Cholangitis APD334 - Primary Biliary Cholangitis | Phase 2 | Terminated | Arena Pharmaceuticals | 2 | 2017-12-29 | 2022-03-24 |
| Study of E6011 in Japanese Subjects With Primary Biliary Cholangitis Inadequately Responding to Ursodeoxycholic Acid E6011, Placebo - Primary Biliary Cholangitis | Phase 2 | Terminated | EA Pharma Co., Ltd. | 29 | 2017-05-29 | 2019-01-04 |
| Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Biliary Cholangitis Without Cirrhosis Cilofexor, Placebo to match cilofexor - Primary Biliary Cholangitis | Phase 2 | Terminated | Gilead Sciences | 71 | 2016-12-01 | 2020-09-22 |
| SMOFlipid to Lessen the Severity of Neonatal Cholestasis SMOFlipid - Cholestasis, Jaundice, Obstructive | Phase 1 / Phase 2 | Terminated | University of Florida | 2 | 2016-05-01 | 2017-04-17 |
| Study to Evaluate the Effects of Two Doses of Seladelpar (MBX-8025) in Subjects With Primary Biliary Cirrhosis (PBC) Placebo Comparator, Experimental: Seladelpar 50 mg, Experimental: Seladelpar / MBX-8025 200 mg - Primary Biliary Cirrhosis (PBC) | Phase 2 | Terminated | Gilead Sciences | 41 | 2015-11-04 | 2025-02-25 |
| IBAT Inhibitor A4250 for Cholestatic Pruritus A4250 - Biliary Cirrhosis, Primary | Phase 2 | Terminated | Sahlgrenska University Hospital | 9 | 2015-01-01 | 2017-02-23 |
| A Safety and Efficacy Study to Determine if Giving Intravenous Fish Oil Helps Children With Liver Disease Omegaven - Cholestasis | Phase 2 | Terminated | University of California, Los Angeles | 62 | 2009-08-01 | 2020-02-26 |
| Compassionate Use of Omegaven IV Fat Emulsion Omegaven - Cholestasis, Total Parenteral Nutrition-induced Cholestasis | Phase 2 | Terminated | Cindy Haller | 15 | 2008-12-01 | 2017-03-10 |
| Study of INT 747 in Combination With URSO in Patients With Primay Biliary Cirrhosis (PBC) INT-747, Ursodeoxycholic Acid (URSO), Placebo - Liver Cirrhosis, Biliary | Phase 2 | Terminated | Intercept Pharmaceuticals | 165 | 2007-10-01 | 2024-02-06 |
| SAMe to Treat Biliary Cirrhosis Symptoms S-adenosyl-methionine (SAMe) capsules - Liver Cirrhosis, Biliary | Phase 2 | Terminated | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 50 | 2005-07-25 | 2017-07-02 |
| Primary Biliary Cirrhosis: Investigating A New Treatment Option Using NI-0801, an Anti-CXCL10 Monoclonal Antibody NI-0801 - Primary Biliary Cirrhosis | Phase 2 | Terminated | Light Chain Bioscience - Novimmune SA | 2014-04-04 |
Liver Cirrhosis, Biliary (12) · Pruritus (3) · Fibrosis (2) · Hyperphagia (2) · Enterocolitis, Necrotizing (1) · Fatigue (1) · Intrahepatic Cholestasis of Pregnancy (1) · Jaundice, Obstructive (1) · Liver Diseases (1)
Bile Duct Diseases (16) · Biliary Tract Diseases (16) · Digestive System Diseases (16) · Pathological Conditions, Signs and Symptoms (15) · Pathologic Processes (13) · Cholestasis, Intrahepatic (12) · Liver Cirrhosis (12) · Liver Diseases (11) · Fibrosis (10) · Signs and Symptoms (5) · Skin Manifestations (4) · Skin Diseases (3) · Skin and Connective Tissue Diseases (3) · Signs and Symptoms, Digestive (2)
fish oil triglycerides (2) · obeticholic acid (2) · (2-methyl-4-(5-methyl-2-(4-trifluoromethyl-phenyl)-2H-(1,2,3)triazol-4-ylmethylsulfanyl)phenoxy)acetic acid (1) · Bezafibrate (1) · Capsules (1) · Parenteral Nutrition (1) · S-Adenosylmethionine (1) · SMOFlipid (1) · Ursodeoxycholic Acid (1) · baricitinib (1) · cilofexor (1) · difelikefalin (1) · etrasimod (1) · quetmolimab (1) · volixibat (1)
Gilead Sciences (2) · Intercept Pharmaceuticals (2) · Arena Pharmaceuticals (1) · Biocad (1) · Cara Therapeutics, Inc. (1) · Cindy Haller (1) · EA Pharma Co., Ltd. (1) · Eli Lilly and Company (1) · Light Chain Bioscience - Novimmune SA (1) · Mirum Pharmaceuticals, Inc. (1) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) · Sahlgrenska University Hospital (1) · University of California, Los Angeles (1) · University of Florida (1)
United States (11) · United Kingdom (6) · Canada (3) · Germany (3) · Australia (2) · Austria (2) · France (2) · Netherlands (2) · New Zealand (2) · Poland (2) · Spain (2) · Belgium (1) · Croatia (1) · Czechia (1) · Estonia (1)
Arena CT.gov Administrator (1) · Cindy Haller, MD (1) · David A Shapiro, MD (1) · Hanns-Ulrich Marschall, MD (1) · Josef Neu, MD (1) · Kara L Calkins, MD (1) · Lynda Szczech (1) · Marina Maevskaya (1) · Pol F Boudes, M.D. (1)
PMID 23894176, PMID 25500425, PMID 25543678, PMID 28521607, PMID 28818518, PMID 30411372, PMID 30900274, PMID 32072161, PMID 41603551
2015 (1), 2016 (1)